Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
17.7
39.48
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ARWR stock under the Base Case scenario is 28.34 USD. Compared to the current market price of 21.63 USD, Arrowhead Pharmaceuticals Inc is Undervalued by 24%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Arrowhead Pharmaceuticals Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ARWR cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Arrowhead Pharmaceuticals Inc
Balance Sheet Decomposition
Arrowhead Pharmaceuticals Inc
Current Assets | 450.1m |
Cash & Short-Term Investments | 436.7m |
Other Current Assets | 13.4m |
Non-Current Assets | 433.7m |
PP&E | 420.3m |
Intangibles | 9m |
Other Non-Current Assets | 4.5m |
Current Liabilities | 96.7m |
Accounts Payable | 26.6m |
Accrued Liabilities | 69.7m |
Other Current Liabilities | 417k |
Non-Current Liabilities | 456.5m |
Other Non-Current Liabilities | 456.5m |
Earnings Waterfall
Arrowhead Pharmaceuticals Inc
Revenue
|
19.6m
USD
|
Operating Expenses
|
-566.9m
USD
|
Operating Income
|
-547.2m
USD
|
Other Expenses
|
8.6m
USD
|
Net Income
|
-538.6m
USD
|
Free Cash Flow Analysis
Arrowhead Pharmaceuticals Inc
USD | |
Free Cash Flow | USD |
Arrowhead reported a net loss of $170.8 million for Q3 2024, largely due to increased R&D expenses and decreased revenue. The company is transitioning into a commercial stage, focusing on launching its first product, plozasiran, aimed at familial chylomicronemia syndrome (FCS) by next year's end, supported by successful Phase III trials. A recent $500 million credit facility significantly bolstered Arrowhead's balance sheet, ensuring robust liquidity. Arrowhead is also advancing clinical trials in multiple therapeutic areas, including its pipeline of RNAi therapeutics, with further updates anticipated at upcoming webinars and conferences.
What is Earnings Call?
ARWR Profitability Score
Profitability Due Diligence
Arrowhead Pharmaceuticals Inc's profitability score is 9/100. The higher the profitability score, the more profitable the company is.
Score
Arrowhead Pharmaceuticals Inc's profitability score is 9/100. The higher the profitability score, the more profitable the company is.
ARWR Solvency Score
Solvency Due Diligence
Arrowhead Pharmaceuticals Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Score
Arrowhead Pharmaceuticals Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ARWR Price Targets Summary
Arrowhead Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for ARWR is 48.23 USD with a low forecast of 20.2 USD and a high forecast of 74.55 USD.
Dividends
Current shareholder yield for ARWR is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The company is headquartered in Pasadena, California and currently employs 329 full-time employees. The firm uses a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. The firm is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The firm's pipeline includes ARO-APOC3 for hypertriglyceridemia, ARO-ANG3 for dyslipidemia, ARO-HSD for liver disease, ARO-ENaC for cystic fibrosis, ARO-HIF2 for renal cell carcinoma, ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-LUNG2 for chronic obstructive pulmonary disorder, and ARO-COV for the coronavirus that causes COVID-19 and other possible future pulmonary-borne pathogens.
Contact
IPO
Employees
Officers
The intrinsic value of one ARWR stock under the Base Case scenario is 28.34 USD.
Compared to the current market price of 21.63 USD, Arrowhead Pharmaceuticals Inc is Undervalued by 24%.